Drug General Information (ID: DDIHG42XN0)
Drug Name			Relugolix		Drug Info		Ivosidenib		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Gonadotropin-Releasing Hormone Antagonists				Antineoplastics
Structure

Mechanism of Relugolix-Ivosidenib Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Relugolix				Ivosidenib
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Relugolix and Ivosidenib

Recommended Action
Management		Coadministration of ivosidenib with other drugs that can prolong the QT interval should generally be avoided. Otherwise, close monitoring of electrocardiograms and electrolytes is recommended. If QT prolongation occurs during treatment, withhold and/or reduce dose in accordance with the product labeling. Ivosidenib should be permanently discontinued in patients who develop QT prolongation with signs or symptoms of life-threatening arrhythmia.

References
1	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.